— Know what they know.
Not Investment Advice

IOBT NASDAQ

IO Biotech, Inc.
1W: -33.2% 1M: -96.8% 3M: -98.8% YTD: -99.1% 1Y: -99.3% 3Y: -99.7%
$0.01
Last traded 2026-04-20 — delisted
NASDAQ · Healthcare · Biotechnology · $885690 mcap · 60M float · 33.10% daily turnover · Short 52% of daily vol

Balance Sheet Trends

Total Assets
$68M -55.1% ▼
5Y CAGR: +48.3%
Total Liabilities
$21M +17.8% ▲
5Y CAGR: +13.7%
Shareholders Equity
$47M -64.7% ▼
Cash & Investments
$60M -58.1% ▼
5Y CAGR: +50.2%
Total Debt
$2M -23.2% ▼
5Y CAGR: -26.1%
Net Debt
-$58M +58.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$3M$212M$143M$143M$60M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$3M$212M$143M$143M$60M
Net Receivables$2M$2M$2M$1M$1M
Inventory$0$0$0$0$0
Other Current Assets$371K$149K$685K$754K$803K
Total Current Assets$6M$222M$148M$147M$65M
Property, Plant & Equip.$0$155K$3M$3M$2M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$268K$268K$0$268K
Other Non-Current Assets$18K$127K$84K$357K$117K
Total Non-Current Assets$18K$550K$4M$3M$3M
Total Assets$6M$222M$152M$151M$68M
— Liabilities —
Accounts Payable$522K$4M$4M$4M$5M
Short-Term Debt$0$0$515K$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$461K$4M$5M$500K
Total Current Liabilities$3M$10M$11M$16M$19M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$59K$0$0$0
Total Non-Current Liabilities$0$59K$2M$2M$1M
Total Liabilities$3M$10M$13M$18M$21M
— Equity —
Common Stock$8K$29K$29K$66K$66K
Retained Earnings-$38M-$106M-$178M-$264M-$359M
Accumulated OCI$2M-$1M-$10M-$10M-$7M
Total Stockholders Equity$3M$212M$139M$133M$47M
Total Liabilities & Equity$6M$222M$152M$151M$68M
— Key Metrics —
Total Debt$0$0$3M$2M$2M
Net Debt-$3M-$212M-$140M-$141M-$58M
Total Investments$0$268K$268K$0$268K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms